Latest From Lupin Ltd.
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Lupin Laboratories
- Parent & Subsidiaries
- Lupin Ltd.
- Senior Management
Vinita Gupta, CEO
Ramesh Swaminathan , CFO
- Contact Info
Phone: (91) 22 6640 2222
B/4 Laxmi Towers, Bandra Kurla Complex
Mumbai, 400 051
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.